InsidersTradesSigma
INCYTE CORP Stock: price and insider trades · United States · SEC (Form 4)
Track the INCYTE CORP stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares are listed on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, INCYTE CORP has recorded 444 reports. Market capitalisation: €23.1bn. The latest transaction was filed on 7 July 2026 (Retenue fiscale). Among the most active insiders: BAKER BROS. ADVISORS LP. Every trade is accessible without an account.
444
Insider Decl.
0
Thresholds
€3m
44 ops.
Buy Volume
€14m
42 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate INCYTE CORP Buy (bullish), based on 22 analysts. Average price target: US$111.27.
48Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 1,761 of 25,619 companies
76.9
score / 100
Value60
Quality94
FCF yld5.8%
Earn yld5.6%
EV/EBITDA13.1x
ROE31%
Gross mgn93%
Net mgn25%
Debt/EBITDA0.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 7 July 2026
Declarations444 total
4,779 shares@ US$116.860.0024% mcap100.0% of flowCommon StockSEC:0001536778-26-000007:0
2,177 shares@ US$116.860.0011% mcap2.0% of flowCommon StockSEC:0001673776-26-000015:0
477 shares@ US$116.860.0002% mcap8.3% of flowCommon StockSEC:0001912317-26-000011:0
350 shares@ US$116.860.0002% mcap100.0% of flowCommon StockSEC:0002079962-26-000007:0
400 sharesCommon StockSEC:0001193125-26-294712:0
400 sharesCommon StockSEC:0001193125-26-294712:1
1,642 sharesCommon StockSEC:0001193125-26-265952:0
1,642 sharesCommon StockSEC:0001193125-26-265952:1
1,642 sharesCommon StockSEC:0001221590-26-000017:0
1,642 sharesCommon StockSEC:0001213029-26-000005:0
1,642 sharesCommon StockSEC:0001409601-26-000008:0
1,642 sharesCommon StockSEC:0001405288-26-000006:0
1,642 sharesCommon StockSEC:0001177917-26-000011:0
25,469 shares@ US$95.590.011% mcap44.4% of flowCommon StockSEC:0001205703-26-000017:0
15,000 shares@ US$84.530.0057% mcap50.0% of flowCommon StockSEC:0001221590-26-000011:0
13,059 shares@ US$97.100.0057% mcap50.0% of flowCommon StockSEC:0001221590-26-000011:1
15,000 shares@ US$84.530.0057% mcap40.0% of flowCommon StockSEC:0001409601-26-000006:0
15,000 shares@ US$94.930.0064% mcap45.0% of flowCommon StockSEC:0001409601-26-000006:1
6,077 shares@ US$64.250.0017% mcap7.0% of flowCommon StockSEC:0001205703-26-000012:0
12,590 shares@ US$71.930.0040% mcap16.3% of flowCommon StockSEC:0001205703-26-000012:1
18,667 shares@ US$96.500.0080% mcap32.4% of flowCommon StockSEC:0001205703-26-000012:2
4,649 shares0Common StockSEC:0001628280-25-016580:0
37,198 shares0Common StockSEC:0001628280-25-016576:0
11,159 shares0Common StockSEC:0001628280-25-016572:0
66,899 shares0Common StockSEC:0001628280-25-016570:0
25 of 444 declarations
About INCYTE CORP
Incyte Corp. (NASDAQ: INCY) is a U.S.-based biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies for areas of high unmet medical need. Its global headquarters is in Wilmington, Delaware, United States, and the company maintains operations across North America, Europe, and Asia. Incyte was founded in 1991 and went public in 1993. It initially built its reputation in genomics and drug discovery before evolving into a more fully integrated therapeutics company with a core focus on oncology, hematology, and inflammation/autoimmunity. ([investor.incyte.com](https://investor.incyte.com/resources/investor-faqs?utm_source=openai)) From an investor perspective, Incyte is best viewed as a specialty biotech with a combination of marketed products and a substantial clinical pipeline. The company’s commercial portfolio includes Jakafi/Jakavi (ruxolitinib), a well-established therapy in certain myeloproliferative disorders; Opzelura (ruxolitinib cream), which gives Incyte a dermatology franchise; and Zynyz (retifanlimab), its immuno-oncology asset. Incyte also commercializes tafasitamab through Monjuvi in the United States and Minjuvi internationally, strengthening its position in hematology and lymphoma. ([incyte.com](https://incyte.com/?utm_source=openai)) Competitively, Incyte stands out by combining a meaningful commercial base with a research engine aimed at differentiated, mechanism-driven medicines. That matters in the highly competitive biotech sector, where execution on late-stage development and regulatory approvals can determine long-term value creation. The company’s strategy is to target diseases where clinical need remains significant and where its scientific expertise can support premium, specialty-market positioning. At the same time, investors should recognize that revenue remains concentrated in a limited number of key franchises, which is common in biotech but still a factor to monitor. ([incyte.com](https://incyte.com/?utm_source=openai)) Geographically, Incyte has a strong U.S. base but a genuinely international footprint, with commercial and development activities extending into Europe and Asia. Recent company highlights include new 2025 clinical data for Opzelura, povorcitinib in hidradenitis suppurativa, INCA033989 in myelofibrosis, and other pipeline assets such as bispecific and KRAS-focused programs. In late 2025 and early 2026, Incyte also reported or advanced multiple regulatory milestones for Zynyz and Minjuvi, underscoring a dense stream of clinical, regulatory, and commercial catalysts. For investors following SEC Form 4 insider activity, the company’s profile on the NYSE/NASDAQ universe is that of a U.S.-listed biotech with recurring commercial revenues and a catalyst-rich development portfolio. ([investor.incyte.com](https://investor.incyte.com/news-releases/news-release-details/incyte-announces-new-data-phase-3b-true-ad4-trial-opzelurar?utm_source=openai))
